Search

The European Network for Gynaecological Oncological Trial groups (ENGOT) is a research network of the European Society of Gynaecological Oncology and was founded in Berlin in October 2007. Earlier, we reported on the ENGOT minimal requirements for trials between academic groups and pharmaceutical companies. In this paper, we summarize the roadmap for performing trials in the ENGOT framework. In this roadmap, we define how an ENGOT trial should be set up and discuss the following items: What are the conditions to classify a study as an ENGOT trial? What is an ENGOT protocol? How are an ENGOT protocol, informed consent (ICF), and case report form (CRF) produced? How is the center selection and feasibility performed in ENGOT trials? How are regulatory and operational tasks handled? How should a confidentiality agreement between the industry and the whole ENGOT network be negotiated? How are contracts made between the industry and ENGOT and between ENGOT groups? How are funding, insurance, and communication flow arranged in ENGOT trials? What are the requirements for conducting substudies and what are the tasks for the leading group in an ENGOT trial? A template of a confidentiality agreement, a checklist of ENGOT criteria for new study proposals, and guidelines for authorship are also provided.

The extent to which enterprise resource planning (ERP) systems deliver value for organizations has been debated. In this study, we argue that the presence of appropriate organizational resources is essential for capturing the potential of ERP implementation. We investigate the relationship between ERP implementation and two organizational resources, specifically, Intellectual Capital (IC) and Organizational Learning Capability (OLC) to enrich the understanding of the way the value of ERP implementations can be realized. A sample of 226 manufacturing firms in Vietnam was surveyed to test the theoretical model. Structural equation modelling with partial least square method and two approaches for moderation analysis were used to analyze the data. The results indicate that ERP implementation scope has a positive impact on intellectual capital (IC). However, firms need to build a certain level of OLC to utilize ERP implementation for the enhancement of IC., Comment: ISBN# 978-0-646-95337-3 Presented at the Australasian Conference on Information Systems 2015 (arXiv:1605.01032)

The histories of the persons dying in a country district during 1973 were examined. The number of visits to the doctors, and also the days spent in hospital by their close relatives in the two years before 1973 were compared with those in the two years that followed. A control group was also examined. There were significant differences in these figures. Analysis suggests that ill health in those aged 50 and over increases after the death of a close relative. A group which is "at risk" after bereavement appears to have been identified.

n/a

n/a

n/a

n/a

n/a

Irish breast cancer survivor's needs have not been studied. Physical, psychological, social and spiritual concerns were investigated. Patient satisfaction with hospital discharge, GP follow-up, and the benefit of a discharge pack was investigated. A cohort of patients from the South East Cancer Centre was identified.localized breast cancer, completion of adjuvant therapy, GP-led follow-up in the last 5 years. An anonymous questionnaire was developed, and ethical approval obtained. Subgroup analyses for age and time since diagnosis and discharge were completed. 80 patients were identified. 44 patients (55%) completed the questionnaire, 5 (6%) were excluded. Commonest concerns included: fatigue (51%), fear of recurrence (69%) and second cancers concerns (69%) 23 (59%) and 25 patients (64%) were satisfied with discharge and GP follow-up respectively. 27 patients (67%) reported benefit from a discharge pack. Irish breast cancer survivors had concerns, and were satisfied with GP follow-up.

The first version of ENGOT’s Requirements for Trials Between Academic Groups and Industry Partners in Europe was published 2010. This first update integrates the experiences made by the ENGOT network and the cooperative group studies while performing, analyzing, and publishing -among others - three large phase III trials. Furthermore, progress in European legislation and its impact on clinical studies in Europe have been considered in this update process.